Skip to main content

Experimental and Clinical Results of Perioperative Treatment with Recombinant Human Erythropoietin

  • Conference paper

Abstract

The side effects of allogeneic blood transfusions are nowadays well known [1]. Especially the risk of transmitting viral infections is a reason to seek methods to reduce the need for allogeneic blood transfusions. Many retrospective studies suggest that in patients undergoing resection for malignancy there is a further adverse effect of blood transfusions: perioperative transfusions may stimulate tumor growth and therefore worsen the prognosis of these patients [2, 3]. Additionally, the rate of postoperative infectious complications may be increased if blood transfusions are given [4]. All these effects can be avoided if the patient’s own blood is used because this is the safest blood to be transfused. Autologous transfusions can be achieved in several ways: (a) by predeposit autologous blood donations, (b) by preoperative intentional hemodilution, and (c) by reinfusion of blood saved during the operation. In cancer surgery these methods may have their limitations due to logistical problems and anemia. In addition, intraoperative cell saving is not allowed in cancer surgery because of the possibility of introducing metastases.

This research was funded by Cilag, Brussels, Belgium

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Walker RH (1987) Transfusion risks. Am J Clin Pathol 88: 374–378

    PubMed  CAS  Google Scholar 

  2. Marquet RL, de Bruin RWF, Dallinga RJ, Kumar S, Jeekel J (1986) Modulation of tumor growth by allogeneic blood transfusion. J Cancer Res Clin Oncol 111: 50–53

    Article  PubMed  CAS  Google Scholar 

  3. Blumberg N, Heal JM (1989) Transfusion and host defences against cancer recurrence and infection. Transfusion 29: 236–245

    Article  PubMed  CAS  Google Scholar 

  4. Tartter PI (1988) Blood transfusion and infectious complications following colorectal cancer surgery. Br J Surg 75: 789–792

    Article  PubMed  CAS  Google Scholar 

  5. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM (1986) Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic haemodialysis. Lancet 2: 1175–1178

    Article  PubMed  CAS  Google Scholar 

  6. Hoynck van Papendrecht MAW, Jeekel J, Marquet RL. Dosage of recombinant human erythropoietin in autologous blood donation programs; a study in rats (submitted)

    Google Scholar 

  7. Levine EA, Rosen AL, Gould SA et al. (1988) Recombinant human erythropoietin and autologous blood donation. Surgery 104: 365–369

    PubMed  CAS  Google Scholar 

  8. Goodnough LT, Rudnick S, Price TH et al. (1989) Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 321: 1163–1168

    Article  PubMed  CAS  Google Scholar 

  9. Levine EA, Gould SA, Rosen AL et al. (1989) Perioperative recombinant human erythropoietin. Surgery 106: 423–428

    Google Scholar 

  10. Krieter H, Brückner UB, Krumwieh D, Seiler FR, Messmer K (1990) Erythropoietin accelerates the recovery from extreme hemodilution: a randomized, placebo-controlled study in dogs. Eur Surg Res 22: 121–127

    Article  PubMed  CAS  Google Scholar 

  11. Muirhead N, Hodsman AB (1990) Occult infection and resistance of anaemia to rHuEPO therapy in renal failure. Nephrol Dial Transplant 5: 232–234

    PubMed  CAS  Google Scholar 

  12. Hoynck van Papendrecht MAW, Jeekel J, Busch ORC, Marquet RL. The efficacy of recombinant erythropoietin to obviate the need for blood transfusions in surgery (in preparation)

    Google Scholar 

  13. Adamson JW, Eschbach JW (1990) The use of recombinant human erythropoietin (rHuEPO) in humans. Cancer Surv 9: 157–167

    PubMed  CAS  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Busch, O.R.C., Hoynck van Papendrecht, M.A.W., Marquet, R.L., Jeekel, J. (1992). Experimental and Clinical Results of Perioperative Treatment with Recombinant Human Erythropoietin. In: Pagel, H., Weiss, C., Jelkmann, W. (eds) Pathophysiology and Pharmacology of Erythropoietin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77074-6_40

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-77074-6_40

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-77076-0

  • Online ISBN: 978-3-642-77074-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics